Evogene (NASDAQ:EVGN) Shares Cross Above Fifty Day Moving Average – Should You Sell?

Evogene Ltd. (NASDAQ:EVGN)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.25 and traded as high as $1.35. Evogene shares last traded at $1.28, with a volume of 139,685 shares.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, October 8th. Alliance Global Partners upgraded Evogene to a “strong-buy” rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.50.

Evogene Stock Performance

The stock’s fifty day moving average price is $1.25 and its 200-day moving average price is $1.25. The company has a market capitalization of $6.87 million, a P/E ratio of -0.57 and a beta of 1.56.

Institutional Investors Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. Jane Street Group LLC boosted its holdings in Evogene Ltd. (NASDAQ:EVGN) by 58.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,732 shares of the biotechnology company’s stock after acquiring an additional 12,387 shares during the period. Jane Street Group LLC owned 0.63% of Evogene worth $42,000 as of its most recent filing with the Securities and Exchange Commission. 10.40% of the stock is owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.